CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionOperating margin is 36.2%, higher than 95% of its Medical Devices peers (median 8.1%)
- FinancialsHigh earnings quality
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.00%
Annual Rate
CNY 1.04Paid annual
Payout Ratio
91.0%High
Payback Period
49.7 yr
Last Ex-Dividend
Jun 17, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.17BCNY620.28M · vs all stocks (USD)
Trailing P/E
20.14xvs Medical Devices peers
Revenue (TTM)
592.88MCNY88.17M · vs all stocks (USD)
Profit Margin
36.06%vs Medical Devices peers
Beta
0.4800xvs all stocks
52-Week Change
-38.20%vs all stocks
Market Capitalization
4.17BCNY620.28M · vs all stocks (USD)
Enterprise Value
2.03BCNY301.24M · vs all stocks (USD)
Trailing P/E
20.14xvs Medical Devices peers
Price to Sales (TTM)
7.27xvs Medical Devices peers
Price to Book (MRQ)
1.70xvs Medical Devices peers
Enterprise to Revenue
3.42xvs Medical Devices peers
Enterprise to EBITDA
9.47xvs Medical Devices peers
Gross Margin
73.37%vs Medical Devices peers
Profit Margin
36.06%vs Medical Devices peers
Operating Margin
36.22%vs Medical Devices peers
Return on Assets (TTM)
4.70%vs Medical Devices peers
Return on Equity (TTM)
8.57%vs Medical Devices peers
Revenue (TTM)
592.88MCNY88.17M · vs all stocks (USD)
Revenue per Share (TTM)
7.37CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-7.30%vs Medical Devices peers
Gross Profit (TTM)
421.02MCNY62.61M · vs all stocks (USD)
EBITDA (TTM)
248.90MCNY37.01M · vs all stocks (USD)
Net Income (TTM)
213.82MCNY31.80M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-12.10%vs Medical Devices peers
Operating Cash Flow (TTM)
218.98MCNY32.56M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-15.98MCNY-2.38M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.04CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
2.00%vs all stocks
Payout Ratio
91.04%vs Medical Devices peers
Minority Interest (Equity)
-465.39KCNYFY2025 · Dec 31, 2025Revenue
593.74MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
171.67MCNYFY2025 · Dec 31, 2025Gross Profit
422.07MCNYFY2025 · Dec 31, 2025Operating Income
223.81MCNY33.28M · vs all stocks (USD)
Pre-tax Income
262.05MCNYFY2025 · Dec 31, 2025Income Tax Expense
40.61MCNYFY2025 · Dec 31, 2025Net Income
221.44MCNYFY2025 · Dec 31, 2025EBIT
262.15MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
275.88MCNYFY2025 · Dec 31, 2025Research & Development
75.89MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
38.82MCNYFY2025 · Dec 31, 2025Other Operating Expenses
9.51MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
8.79MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
105.80KCNYFY2025 · Dec 31, 2025EPS (Basic)
2.76CNYFY2025 · Dec 31, 2025EPS (Diluted)
2.75CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
80.33MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
80.33MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
221.44MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
276.79KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
230.08MCNYFY2025 · Dec 31, 2025Free Cash Flow
167.11MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.04BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
221.44MCNYFY2025 · Dec 31, 2025Other Non-cash Items
8.62MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
10.08MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.06MCNYFY2025 · Dec 31, 2025Capital Expenditures
-62.97MCNYFY2025 · Dec 31, 2025Other Investing Activity
-22.63MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-85.60MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
35.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-111.20MCNYFY2025 · Dec 31, 2025Other Financing Charges
19.76MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-56.43MCNYFY2025 · Dec 31, 2025Shares Outstanding
81.12MSharesUpdated Aug 21, 2026Float Shares
29.11MSharesUpdated Aug 21, 2026% Held by Insiders
66.88%vs all stocks
% Held by Institutions
7.07%vs all stocks
Total Cash (MRQ)
2.27BCNY337.85M · vs all stocks (USD)
Total Cash per Share (MRQ)
28.01CNYUpdated Aug 21, 2026Total Debt (MRQ)
71.55MCNY10.64M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0281xvs Medical Devices peers
Current Ratio (MRQ)
13.66xvs Medical Devices peers
Book Value per Share (MRQ)
31.42CNYUpdated Aug 21, 2026Total Assets
2.68BCNY398.04M · vs all stocks (USD)
Total Current Assets
2.09BCNYFY2025 · Dec 31, 2025Total Liabilities
160.37MCNYFY2025 · Dec 31, 2025Total Non-current Assets
582.54MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
8.47MCNYFY2025 · Dec 31, 2025Total Current Liabilities
151.90MCNYFY2025 · Dec 31, 2025Cash
1.04BCNYFY2025 · Dec 31, 2025Cash Equivalents
141.46MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.18BCNYFY2025 · Dec 31, 2025Other Short-term Investments
592.42MCNYFY2025 · Dec 31, 2025Accounts Receivable
54.41MCNYFY2025 · Dec 31, 2025Inventory
59.65MCNYFY2025 · Dec 31, 2025Accounts Payable
43.51MCNYFY2025 · Dec 31, 2025Short-term Debt
36.41MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.18MCNYFY2025 · Dec 31, 2025Long-term Debt
845.21KCNYFY2025 · Dec 31, 2025Common Stock (Book)
81.12MCNYFY2025 · Dec 31, 2025Retained Earnings
665.47MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.52BCNY374.20M · vs all stocks (USD)
Treasury Stock
13.65MCNYFY2025 · Dec 31, 202552-Week Low
49.00CNYUpdated Aug 21, 202652-Week High
84.80CNYUpdated Aug 21, 202652-Week Change
-38.20%vs all stocks
Beta
0.4800xvs all stocks
50-Day MA
53.03CNYUpdated Aug 21, 2026200-Day MA
57.78CNYUpdated Aug 21, 2026Avg 10-Day Volume
840.16KSharesUpdated Aug 21, 2026Avg 30-Day Volume
598.96KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
2.65CNYUpdated Aug 21, 20268 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 36.2%, higher than 95% of its Medical Devices peers (median 8.1%)Significant
Operating margin: 0.36Industry median: 0.08Industry P95: 0.34Peers compared: 102
Profit margin is 36.1%, higher than 95% of its Medical Devices peers (median 4.8%)Significant
Profit margin: 0.36Industry median: 0.05Industry P95: 0.32Peers compared: 102
Current ratio is 13.67×, higher than 95% of its Medical Devices peers (median 3.83×)Significant
Current ratio: 13.66Industry median: 3.83Industry P95: 12.54Peers compared: 102
Financial Health
High earnings qualityNotable
Earnings Quality Score: 0.55
High structural barrier to entryNotable
Barrier to Entry: 0.71
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Kexing Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Weixinkang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
TTY Biopharm Company Limited
Tier 1ProductionApproval-Gated PipelineRule
Beijing Scitop Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Allogene Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Kinetic Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tectonic Therapeutic Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hainan Shuangcheng Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cerus Corporation
Tier 1ProductionApproval-Gated PipelineRule
Jinling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
One Career Inc.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsLow-Leverage Liquidity Configuration
Hangzhou Sunrise Technology Co., Ltd.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsLow-Leverage Liquidity Configuration
Amoy Diagnostics Co., Ltd.
8 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsLow-Leverage Liquidity Configuration